 CytoDyn Inc revealed that it has submitted to the US Food and Drug Administration FDA an application for Breakthrough Therapy designation BTD for its flagship drug leronlimab as a potential treatment for Metastatic Triple-Negative Breast Cancer mTNBC. The Vancouver, Washington-based late-stage biotechnology company said the application is based on the data analysis reported by the company on November 3, 2021. 